Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
doi 10.2217/lmt-2020-0005
Full Text
Open PDFAbstract
Available in full text
Date
March 19, 2020
Authors
Publisher
Future Medicine Ltd